奥维迪治疗公司2025年季度报告

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange ActoIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yeso Nox Unregistered Sales of Equity Securities and Use of Proceeds Signatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of theSecurities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or theExchange Act. All statements other than statements of historical fact are “forward-looking statements” for purposes of this QuarterlyReport on Form 10-Q. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,”“assume,” “believe,” “contemplate,” "continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” our ability to identify additional novel compounds with significant commercial potential to acquire or in-license; the potential use, development and therapeutic potential of the drug candidates in our pipeline;our ability to develop medical therapies that deliver preferable safety and tolerability profiles to approved drugs; our expectations regarding the duration of our cash runway and the expectation that it will support our operations and development programs; our estimates regarding expenses, future revenue including any royalty or milestone payments, capital requirementsand needs for additional financing; our ability to obtain regulatory approval of our current and future drug candidates;our expectations regarding the timing of initiation, completion, and results and data from clinical trials and potential our expectations regarding the potential market size for drug candidates and the rate and degree of market acceptance of such drug candidates; the implementation of our business model and strategic plans for our business and drug candidates, including the developments or disputes concerning our intellectual property or other proprietary rights;our ability to maintain and establish collaborations or obtain additional funding; our expectations regarding government and third-party payor coverage and reimbursement;our ability to compete in the markets we serve; the impact of government laws and regulations; developments relating to our competitors and our industry; interim topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data;the impact of geopolitical tensions, including war or the perception that hostilities may be imminent, adverse global economic conditions, terrorism, natural disasters or public health crises on our operations, research and developmentand clinical trials and potential disruption in the operations and business of third parties and collaborators with the factors that may impact our financial results.Factors that may cause actual results to differ materially from current expectations include, among other things, those setforth in Part II, Item 1A, “Risk Factors,” herein and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subjectto these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. Although webelieve that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required bylaw, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomesavailable in the future.This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our government data and similar sources and we have not independently verified the data from third party sources. In some cases, we donot expressly refer to the sources from which these data are derived. In this Quarterly Report on Form 10-Q, unless otherwise stated or as the context otherwise requires, references to “Ovid,” the“Company,” “we,” “us,” “our” and similar references refer to Ovid Therapeutics Inc. and its wholly owned subsidiaries. This Quarterly Report on Form 10-Q also contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience,trademarks and trade names referred to, including logos, artwork and other visual displays, may